Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth
Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following:
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.
Website: https://www.actiniumpharma.com
Social Media Links:
Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc-
Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-Inc
Twitter: https://twitter.com/ActiniumPharma
People also listened to this: The Miracle of Enzymes to Heal Digestive Problems
Create your
podcast in
minutes
It is Free